People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.

The phase 3 STEP UP trial enrolled 1407 adults aged 18 years and older with a body mass index of at least 30kg/m2 and without diabetes.

Semaglutide sells for $997 a month when branded under Ozempic and $1,349 a month for Wegovy. The haircut to Ozempic may have a spillover effect on competitor drugs from Eli Lilly — Mounjaro and ...

Olivia Petter, The Independent If someone had told my teenage self that a magical drug would make me thin, I’d have taken it ...

New Activin R-based medications can emerge as perfect solutions for balancing weight loss and muscle building, making a ...

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

After Novo Nordisk (NVO) reported results from its Phase 3b STEP UP trial, which showed that adults with obesity achieved a 20.7% weight loss ...

The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare ...

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

Medicare to negotiate prices for blockbuster drugs like Ozempic and Wegovy, potentially saving enrollees millions.

Semaglutide (Ozempic) is 1 of 15 medications that will be included in yearly price negotiations between Medicare and ...